Cryoport vs Maravai LifeSciences
CYRX and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYRX and MRVI compare
Maravai LifeSciences is the larger company, worth 1.9 times as much as Cryoport ($1.9B against $1000M).
Cryoport grew revenue faster over the last twelve months (12.1% versus −5.0% for Maravai LifeSciences).
Cryoport keeps more of each dollar of sales as profit, with a net margin of −20.1% compared with −37.1% at Maravai LifeSciences.
Cryoport scores higher on the StockData Score (11 against 7 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYRX | MRVI |
|---|---|---|
| Size and price | ||
| Market cap | $1000M | $1.9B |
| Share price | $19.74 | $7.28 |
| Change, 1 year | 128% | 100% |
| Change, 5 years | −70.3% | −82.5% |
| Beta (5Y) | 1.43 | 0.31 |
| Employees | 738 | 435 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.4× (better) | 9.1× |
| P/B | 2.0× (better) | 9.2× |
| FCF yield | −2.0% | −1.9% (better) |
| Fair value | $16.22 | $2.69 |
| Margin of safety | −21.7% (better) | −170% |
| Growth | ||
| Revenue growth (TTM) | 12.1% (better) | −5.0% |
| Revenue growth, 5Y average | 17.5% (better) | −8.1% |
| Net income growth (TTM) | −147% | – |
| EPS growth (TTM) | −164% | – |
| Profitability | ||
| Gross margin | 47.1% (better) | 34.9% |
| Operating margin | −21.2% (better) | −56.1% |
| Net margin | −20.1% (better) | −37.1% |
| FCF margin | −10.7% (better) | −17.2% |
| Return on equity | −7.4% (better) | −32.9% |
| Return on invested capital | −33.0% | −32.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.72 |
| Interest coverage | −18.8× | −4.9× (better) |
| Current ratio | 2.08 | 4.05 (better) |
| Altman Z-score | 1.40 | 4.50 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.9% | 55.5% |
| Held by insiders | 3.6% | 3.6% |
| Insider net buying, 12 months | −$6.3M | $115K (better) |
| Short interest, % of float | 7.1% | 5.6% |
Go deeper
- CYRX stock overview
- CYRX income statement
- CYRX valuation and score
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.